Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib PK in Hepatic Impairment
NCT05552183Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pacritinib in myelofibrosis (MF) (3 arms), sponsored by CTI BioPharma Corp. Primary endpoints: Maximum Plasma Concentration at Day 14, Time to Maximum Concentration at Day 14 and 5 more. Started Dec 2022; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05552183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552183.